Payload Information

General Information of This Payload

Payload ID	PAY0BUPGD
Name	Proprietary DNA topoisomerase I inhibitor
Synonyms	Proprietary DNA topoisomerase I inhibitor Click to Show/Hide
Target(s)	DNA topoisomerase 1 (TOP1)	Target Info

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

AZD-5335 [Phase 1/2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05797168	Phase Status	Phase 1/2
Clinical Description	FONTANA: A modular phase 1/2a, open-label, multi-center study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ascending doses of AZD5335 monotherapy and in combination with anti-cancer agents in participants with solid tumors.
Primary Endpoint	Number of participants with adverse events/serious adverse events, the number of participants with dose limiting toxicity (DLT).
Other Endpoint	Objective Response Rate (ORR), Duration of Response (DoR), Disease Control Rate (DCR), Progression free Survival (PFS), Overall Survival (OS).

References

Ref 1	FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors, NCT05797168

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.